


Supplementary Figure 1

Dexmedetomidine-induced sedation and recovery sleep induce *cfos* expression in overlapping regions of the mouse hypothalamic preoptic area and septum.


(a) Schematic of the preoptic hypothalamic and septal area: left-hand drawing, coronal section, boxed areas, magnified on the right, show the relevant anatomical sites corresponding to the photographs below; (b) Photographs of nuclear *cfos* protein (DAB staining method) 30 minutes after saline, 30 minutes and 1 hour after dexmedetomidine ($100 \mu\text{g kg}^{-1}$) injections or 2 hours into recovery sleep. Abbreviations, LPO, lateral preoptic area; LSV, lateral septum, ventral; MPO, medial preoptic area SHy, septo-hypothalamic nucleus; STLD, stria terminalis lateral dorsal; STMA, stria terminalis medial anterior; VLPO, ventral lateral preoptic area.



Supplementary Figure 2

Induction of hM_3D_q - $mCHERRY$ transgene during recovery sleep in MnPO- $TetTag$ - hM_3D_q mice.


The TetTag AAVs were injected at the midline into the MnPO area. The photographs show coronal sections stained for hM_3D_q - $mCHERRY$ expression (red). The left-hand photograph in the top row shows basal transgene expression with no doxycycline; the middle picture shows induced hM_3D_q - $mCHERRY$ transgene expression in the MnPO area 2 hours into recovery sleep; the third figure shows expression 4 days later with the mice back on doxycycline. The images below show the low expression 4 weeks later and the figure to the right shows the relatively low hM_3D_q - $mCHERRY$ transgene induction following dexmedetomidine sedation. Scale bar, 50 μ m; Abbreviations: LPO, lateral preoptic area; MnPO, median preoptic area; 3V, third ventricle.



Supplementary Figure 3

LPO TetTag expression patterns: Induction of *hM₃D_q-mCherry* expression 2 hours following dexmedetomidine-induced sedation where AAVs were bilaterally injected into the LPO and surrounding areas.


Each letter, A through to L, summarizes the expression in individual mice as seen by serial coronal sectioning through the AAV injection sites. Red indicates *hM₃D_q-mCherry* expression. The boxed sections in animals I-L were mice where *hM₃D_q-mCherry* transgene was induced but there was no behavioral or EEG signs of sedation. Some LPO-*TetTag-hM₃D_q* mice that had been sedated with dexmedetomidine did not show any subsequent CNO-induced behavior at either the EEG or behavioral levels relative to that observed with saline injection. Although the *hM₃D_q-mCherry* gene was clearly induced by dexmedetomidine treatment in these animals, the transgene expression sites were on the lateral margin of the LPO area or even further out laterally (animals I, J, K and L). Thus activating these lateral TetTagged neurons with CNO was not sufficient to induce sleep. One animal, (mouse I), had induced *hM₃D_q* receptor only in the BST areas, but also exhibited no CNO-induced behavior, so BST stimulation alone was not sufficient to recapitulate dexmedetomidine-induced sedation. Abbreviations: BST, bed nucleus stria terminalis; LPO, lateral preoptic area; MPO, medial preoptic area; VLPO, ventral lateral preoptic area.



Supplementary Figure 4

MnPO TetTag expression patterns: Induction of *hM₃D_q-mCherry* expression 2 hours into recovery sleep after sleep deprivation (animals A-F) or two hours following dexmedetomidine-induced sedation (animals G-I) where AAVs were midline-injected into MnPO and surrounding areas.


Each letter, A through to I, summarizes the expression in individual mice as seen by serial coronal sectioning through the AAV injection site. Red indicates induced *hM₃D_q-mCherry* expression. The boxed sections, J-L, were from mice where the *hM₃D_q-mCherry* transgene was induced following sleep-deprivation and recovery sleep, but there was no behavioral or EEG signs of NREM sleep following CNO administration. In animals K & L, for example, the intended midline injection of AAV into MnPO missed, and resulted in unilateral *hM₃D_q-mCherry* induction in the LPO area; but activating these receptors with CNO was insufficient to trigger sleep behavior. Abbreviations: BST, bed nucleus stria terminalis; LPO, lateral preoptic area; MPO, medial preoptic area; VLPO, ventral lateral preoptic area.



Supplementary Figure 5

CNO induces nuclear *fos* expression (green) in *hM₃D_q-mCHERRY* (red) expressing neurons in the LPO area of LPO-TetTag-*hM₃D_q* mice.


Double-label immunocytochemistry with antisera to *mCHERRY* and *fos*. The *hM₃D_q-mCHERRY* expression was induced by a sedative dose ($100 \mu\text{g kg}^{-1}$) of dexmedetomidine and then mice were injected with CNO and their brains taken 2 hours afterwards. Arrows indicate examples of co-labeled cells.



Supplementary Figure 6

TetTagged neurons are excited by CNO and are predominantly GABAergic.



(a) A representative example of the effects of 5 μ M CNO on a *mCHERRY*-positive neuron in LPO-*TetTag-hM₃D_q* mice. On average, neurons ($n=8$; 3 mice) were depolarized by 10.2 ± 2.1 mV. In the example shown, action potential firing was triggered. (b) These neurons were predominantly GABAergic. 84% were *gad1* and/or *gad2* positive, as assayed by single-cell qPCR. The remainder were glutamatergic (*vglut2*-positive). (c) A representative example of the qPCR assay run out on a gel from three of the neurons. LAD, sizes shown are base pairs.



Supplementary Figure 7

Characteristics of natural NREM sleep and circadian body temperature of virally-injected C57BL/6 mice, the strain used for the TetTagging experiments.


(a) Percentage of NREM sleep throughout the 24-hour sleep-wake cycle ($n=10$). (b) Fourier Transform power spectra when the EEG and EMG signals from the natural sleep-wake cycle were scored as either sleep (red) or wake (black). Each spectrum is calculated by combining EEG segments totally 20 minutes. The envelopes represent the s.e.m. The inserts show representative EEG traces, and the accompanying calibration bars represent 100 μ V and 500 msec ($n=10$). (c) Body temperature throughout the normal 24-hour sleep-wake cycle. The envelopes represent the s.e.m. All of these data are for LPO-*TetTag-hM₃D_q* ($n=10$) and MnPO-*TetTag-hM₃D_q* mice ($n=10$) combined, because these were indistinguishable. All data are from 12 hours light: 12 hours dark cycles.



Supplementary Figure 8

SC-*TetTag-hM₃D_q* (negative control) mice

(a), schematic illustrating bilateral injection of the two *TetTag-DREADD* AAVs (AAV- P_{cfos} - tTA and AAV- $P_{TRE-tight}$ - hM_3D_q - $mCHERRY$) into the superior colliculi and the experimental procedures with drug administration and time plan following that outlined in **Fig. 3b**. (b) Four days following either 100 $\mu\text{g kg}^{-1}$ dexmedetomidine-induced sedation or after 2 hours into recovery sleep following sleep deprivation, CNO was administered to SC-*TetTag-hM₃D_q* mice. Open circles ($n=6$): control CNO injection without prior sedation or recovery sleep. Filled red circles ($n=5$): CNO injection after prior dexmedetomidine sedation. Filled red triangles ($n=5$): CNO injection after prior recovery sleep. The mice injected with CNO following dexmedetomidine sedation (two-way ANOVA, $P=0.79$) or recovery sleep (two-way ANOVA, $P=0.71$) were indistinguishable from controls.



Supplementary Figure 9

Knock down of adrenergic α 2A receptor transcripts in the preoptic area (LPO) of the hypothalamus had no effect on dexmedetomidine-induced sedation.

(a) Schematic illustrating bilateral injection of AAVs expressing either *dsRED-mir30-shadra2a* or *dsRED-mir30-shscramble* transgenes into the LPO of adult mice. (b) The total distance travelled in 15 minutes by saline-injected (white bars) or dexmedetomidine-injected ($100 \mu\text{g kg}^{-1}$) (red bars) mice was not significantly different ($n=6$ scramble, $n=7$ shRNA; $P=0.19$) for mice with AAVs expressing either the knock-down or scramble transgenes. The boxes represent the s.e.m, and the bars show the range of the data.